Incipiam Pharma

Incipiam Pharma is a Danish clinical-stage biotechnology company dedicated to developing innovative treatments for patients with rare metabolic diseases. The company's primary focus is on Phenylketonuria (PKU), a genetic condition that requires lifelong management of phenylalanine levels to prevent neurological damage. Their lead candidate, IPP-2011, is a specialized formulation designed to improve the management of PKU by competing with phenylalanine for transport into the brain. Incipiam's strategy involves the "re-innovation" of established compounds to address unmet needs in orphan indications. The company is headquartered in the Medicon Valley region of Denmark and leverages deep expertise in orphan drug development.